Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biodesix (BDSX) Accumulated Expenses (2019 - 2026)

Biodesix filings provide 8 years of Accumulated Expenses readings, the most recent being $5.5 million for Q1 2026.

  • On a quarterly basis, Accumulated Expenses rose 26.74% to $5.5 million in Q1 2026 year-over-year; TTM through Mar 2026 was $5.5 million, a 26.74% increase, with the full-year FY2025 number at $11.0 million, up 9.63% from a year prior.
  • Accumulated Expenses hit $5.5 million in Q1 2026 for Biodesix, down from $11.0 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $11.0 million in Q4 2025 to a low of $747000.0 in Q3 2025.
  • Median Accumulated Expenses over the past 5 years was $5.5 million (2026), compared with a mean of $5.4 million.
  • Biggest five-year swings in Accumulated Expenses: soared 923.8% in 2024 and later crashed 91.27% in 2025.
  • Biodesix's Accumulated Expenses stood at $4.7 million in 2022, then crashed by 78.96% to $983000.0 in 2023, then soared by 923.8% to $10.1 million in 2024, then increased by 9.63% to $11.0 million in 2025, then crashed by 49.82% to $5.5 million in 2026.
  • The last three reported values for Accumulated Expenses were $5.5 million (Q1 2026), $11.0 million (Q4 2025), and $747000.0 (Q3 2025) per Business Quant data.